Security Reports > Galmed Pharmaceuticals
Galmed Pharmaceuticals
Data Breaches, Cyber Attacks and Security Report
https://galmedpharma.com ᛫
Last updated May 26, 2020
https://galmedpharma.com ᛫
Last updated May 26, 2020
UpGuard's Cyber Security Ratings range from 0 to 950. The higher the score, the more likely Galmed Pharmaceuticals is implementing good security practices.
Aramchol is an investigational drug being developed by Galmed Pharmaceuticals as a first-in-class, potentially disease modifying treatment for nonalcoholic steatohepatitis, or NASH, a more advanced condition of non-alcoholic fatty liver disease.Aramchol, a conjugate of Cholic acid and Arachidic acid, is a first in class member of a novel family of synthetic Fatty-Acid/Bile-Acid Conjugates (FABACs). FABACs are composed of endogenic compounds, orally administrated with potentially good safety and tolerability parameters.Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to significantly reduce liver fat content as well as improve metabolic parameters associated with fatty liver disease.
This report shows a preliminary security rating for Galmed Pharmaceuticals. UpGuard scans billions of digital assets daily, in depth, across thousands of vectors. Data leak detection, vulnerability scanning and identity breach detection are just some of the advanced capabilities offered by the UpGuard platform.
Get a deeper scan →Read more about the latest issues in cybersecurity
Compare Galmed Pharmaceuticals's security performance with other companies